Approval Summary: Letrozole (Femara® Tablets) for Adjuvant and Extended Adjuvant Postmenopausal Breast Cancer Treatment: Conversion of Accelerated to Full Approval

On April 30, 2010, the U.S. Food and Drug Administration converted letrozole (Femara®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) from accelerated to full approval for adjuvant and extended adjuvant (following 5 years of tamoxifen) treatment of postmenopausal women with hormone receptor...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Cohen, Martin H., Johnson, John R., Justice, Robert, Pazdur, Richard
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2011
Aiheet:
Regulatory Issues: FDA
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3248775/
https://ncbi.nlm.nih.gov/pubmed/22089970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0287
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia